Xiaoran Liu1, Ran Ran1, Bin Shao1, Hope S Rugo2, Yanlian Yang3, Zhiyuan Hu3, Zewen Wei3, Fengling Wan1, Weiyao Kong1, Guohong Song1, Hanfang Jiang1, Xu Liang1, Ruyan Zhang1, Ying Yan1, Guobing Xu4, Huiping Li1. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China. 2. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco 94115, USA. 3. CAS Key Laboratory of Standardization and Measurement for Nanotechnology, the National Center for Nanoscience and Technology of China, Beijing 100190, China. 4. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Clinical Laboratory, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Abstract
OBJECTIVE: Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis. Circulating tumor cells (CTCs) are a promising predictor for breast cancer prognoses but their reliability regarding progression-free survival (PFS) is controversial. We aim to verify their predictive value in TNBC. METHODS: In present prospective cohort study, we used the Pep@MNPs method to enumerate CTCs in baseline blood samples from 75 patients with TNBC (taken at inclusion in this study) and analyzed correlations between CTC numbers and outcomes and other clinical parameters. RESULTS: Median PFS was 6.0 (range: 1.0-25.0) months for the entire cohort, in whom we found no correlations between baseline CTC status and initial tumor stage (P=0.167), tumor grade (P=0.783) or histological type (P=0.084). However, among those getting first-line treatment, baseline CTC status was positively correlated with ratio of peripheral natural killer (NK) cells (P=0.032), presence of lung metastasis (P=0.034) and number of visceral metastatic site (P=0.037). Baseline CTC status was predictive for PFS in first-line TNBC (P=0.033), but not for the cohort as a whole (P=0.118). This prognostic limitation of CTC could be ameliorated by combining CTC and NK cell enumeration (P=0.049). CONCLUSIONS: Baseline CTC status was predictive of lung metastasis, peripheral NK cell ratio and PFS in TNBC patients undergoing first-line treatment. We have developed a combined CTC-NK enumeration strategy that allows us to predict PFS in TNBC without any preconditions.
OBJECTIVE: Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis. Circulating tumor cells (CTCs) are a promising predictor for breast cancer prognoses but their reliability regarding progression-free survival (PFS) is controversial. We aim to verify their predictive value in TNBC. METHODS: In present prospective cohort study, we used the Pep@MNPs method to enumerate CTCs in baseline blood samples from 75 patients with TNBC (taken at inclusion in this study) and analyzed correlations between CTC numbers and outcomes and other clinical parameters. RESULTS: Median PFS was 6.0 (range: 1.0-25.0) months for the entire cohort, in whom we found no correlations between baseline CTC status and initial tumor stage (P=0.167), tumor grade (P=0.783) or histological type (P=0.084). However, among those getting first-line treatment, baseline CTC status was positively correlated with ratio of peripheral natural killer (NK) cells (P=0.032), presence of lung metastasis (P=0.034) and number of visceral metastatic site (P=0.037). Baseline CTC status was predictive for PFS in first-line TNBC (P=0.033), but not for the cohort as a whole (P=0.118). This prognostic limitation of CTC could be ameliorated by combining CTC and NK cell enumeration (P=0.049). CONCLUSIONS: Baseline CTC status was predictive of lung metastasis, peripheral NK cell ratio and PFS in TNBC patients undergoing first-line treatment. We have developed a combined CTC-NK enumeration strategy that allows us to predict PFS in TNBC without any preconditions.
Entities:
Keywords:
Breast cancer; circulating tumor cell; immunology; nanotechnology
Authors: Joyce O'Shaughnessy; Lee Schwartzberg; Michael A Danso; Kathy D Miller; Hope S Rugo; Marcus Neubauer; Nicholas Robert; Beth Hellerstedt; Mansoor Saleh; Paul Richards; Jennifer M Specht; Denise A Yardley; Robert W Carlson; Richard S Finn; Eric Charpentier; Ignacio Garcia-Ribas; Eric P Winer Journal: J Clin Oncol Date: 2014-10-27 Impact factor: 44.544
Authors: Mark Jesus M Magbanua; Lisa A Carey; Amy DeLuca; Jimmy Hwang; Janet H Scott; Mothaffar F Rimawi; Erica L Mayer; P Kelly Marcom; Minetta C Liu; Francisco J Esteva; John W Park; Hope S Rugo Journal: Clin Cancer Res Date: 2014-12-18 Impact factor: 12.531
Authors: M Banys-Paluchowski; H Schneck; C Blassl; S Schultz; F Meier-Stiegen; D Niederacher; N Krawczyk; E Ruckhaeberle; T Fehm; H Neubauer Journal: Geburtshilfe Frauenheilkd Date: 2015-03 Impact factor: 2.915
Authors: Maria Libera Ascierto; Michael O Idowu; Yingdong Zhao; Hanif Khalak; Kyle K Payne; Xiang-Yang Wang; Catherine I Dumur; Davide Bedognetti; Sara Tomei; Paolo A Ascierto; Anil Shanker; Harry D Bear; Ena Wang; Francesco M Marincola; Andrea De Maria; Masoud H Manjili Journal: J Transl Med Date: 2013-06-12 Impact factor: 5.531
Authors: Lorena Alexandra Lisencu; Sebastian Trancă; Eduard-Alexandru Bonci; Andrei Pașca; Carina Mihu; Alexandru Irimie; Oana Tudoran; Ovidiu Balacescu; Ioan Cosmin Lisencu Journal: Biomedicines Date: 2022-03-25